Consun Pharmaceutical

Company Profile: Consun Pharmaceutical Group (01681.HK) is a modern pharmaceutical enterprise integrating research and development, production, and marketing. Founded in 1997 and listed in Hong Kong in 2013, it has subordinate enterprises including Guangzhou Consun Pharmaceutical Co., Ltd., Consun Pharmaceutical (Inner Mongolia) Co., Ltd., Guangxi Yulin Pharmaceutical Group Co., Ltd., and Consun Pharmaceutical (Khorgos) Co., Ltd. It operates well-known brands such as Consun and Yulin, with business spanning more than 30 countries and regions. In 2019, Consun Pharmaceutical was awarded the title of "Benchmark Enterprise in the Pharmaceutical Industry for the 70th Anniversary of the Founding of the People's Republic of China." In 2020, Consun Pharmaceutical was recognized as an influential brand in the pharmaceutical industry of Guangdong Province. In 2021, Consun Pharmaceutical won the "Most Valuable Brand Award" for the Best Listed Companies in Greater China selected by Gelonghui, and was honored as a "Specialized, Refined, Distinctive, and Innovative Small and Medium-sized Enterprise in Guangdong Province" and "Outstanding Enterprise for Anti-epidemic Contributions in 2020." In 2023, Consun Pharmaceutical Group ranked 22nd on the "2022 TOP 100 Traditional Chinese Medicine Enterprises" list, with a brand value of 11.236 billion CNY. The Group has four production bases in China: Guangzhou, Guangdong; Tongliao, Inner Mongolia; Yulin, Guangxi; and Khorgos, Xinjiang, with over 3,000 employees. The Group is committed to building a "1+6" product portfolio, with nephrology as the flagship, and promotes product lines in imaging, women's and children's health, orthopedics, dermatology, hepatobiliary, and digestive health. It has a rich product mix and continuously carries out technological innovation and new product research and development. Currently, it has 138 product varieties, including 62 traditional Chinese medicine varieties and 76 Western medicine varieties; among them, 33 varieties are included in the National Essential Drugs List, and 67 varieties are included in the National Medical Insurance Drug Catalog. Zhenggu Shui was rated as a "National Geographical Indication Protected Product" in 2010. It also has a professional marketing team covering hospitals and OTC channels, with a distribution network across the country, and has maintained steady and rapid growth in business performance. At present, Consun Pharmaceutical Group has a "Nephrology Drug Research Center" invested by the enterprise, a "Postdoctoral Research Workstation," two provincial "Engineering Technology Research Centers," and three provincial "Enterprise Technology R&D Centers," and conducts in-depth industry-university-research cooperation with renowned universities such as Hong Kong Baptist University, Macau University of Science and Technology, and Southern Medical University. In the future, Consun Pharmaceutical will adhere to its corporate mission of "Inheriting the past, innovating for the future, providing good medicine to benefit the people," strive to "build a nephrology flagship and become a leading pharmaceutical enterprise with multiple specialty advantages," and contribute to human health and life.